Biocon Limited has informed the Exchange regarding a press release dated May 08, 2025, titled "Biocon Q4FY25 Revenue at Rs 4,454 Cr, Up 15%** EBITDA atRs 1,115 Cr; Up 16%; Net Profit at Rs 344 Cr, Up 153% FY25 Revenue at Rs 16,470 Cr; EBITDA at Rs 4,374Cr; Net Profit at Rs 1,013 Cr".
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Biocon reported Q4FY25 consolidated revenue of Rs 4,454 crore, up 12% year-on-year (15% on a like-for-like basis after adjusting for the Branded Formulations India divestment). Q4 EBITDA rose 16% to Rs 1,115 crore with margins of 25%, and net profit jumped 153% to Rs 344 crore, helped by a low base. For the full year FY25, revenue grew 5% to Rs 16,470 crore (8% like-for-like), EBITDA was up 5% at Rs 4,374 crore with margins steady at 27%, and net profit was nearly flat at Rs 1,013 crore (up 30% on a like-for-like basis). The Generics business led growth with a 46% jump in Q4, while Biosimilars grew 9% like-for-like and Syngene rose 11%. The Board has recommended a final dividend of Rs 0.50 per share and approved a fund-raising plan of up to Rs 4,500 crore via QIP, rights issue or other routes, mainly to repay or restructure borrowings. A committee has also been set up to evaluate a potential merger of Biocon Biologics with Biocon Limited.
Strong quarterly earnings, especially in Generics and Biosimilars, should support sentiment, while the proposed Rs 4,500 crore capital raise and possible BBL-BL merger could cause near-term dilution and structural overhang. The small final dividend and flat reported FY25 net profit offer limited cash returns for shareholders.